Petru, E., Andel, J., Angleitner-Boubenizek, L., Steger, G., Bernhart, M., Busch, K., … Zabernigg, A. (2008). Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. Wiener Medizinische Wochenschrift, 158(5–6), 169–173.
To evaluate the efficacy of palonosetron in the clinical practice setting
Patients were given premedication with 0.25 mg palonosetron on day one of each chemotherapy cycle. All patients were prescribed standard antiemetics as recommended in Multinational Association of Supportive Care in Cancer (MASCC) and American Society of Clinical Oncology (ASCO) guidelines. Patients completed questionnaires to document satisfaction with control of nausea and emesis in the acute and delayed phases.
The study was conducted in multiple outpatient settings in Austria.
All patients were in active treatment.
This was a prospective trial.
Palonosetron was found to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) and to provide a significant contribution to the antiemetic armamentarium.
Findings support the effectiveness of palonosetron in management of CINV. Effectiveness in managing nausea, rather than just emesis, is not clear.